Authors
Trisha Dalapati, Caitlin A Williams, Elena E Giorgi, Jillian H Hurst, Savannah Herbek, Jui-Lin Chen, Christina Kosman, Alexandre T Rotta, Nicholas A Turner, Natalie Pulido, Jhoanna N Aquino, Trevor S Pfeiffer, Javier Rodriguez, Genevieve G Fouda, Sallie R Permar, Matthew S Kelly
Publication date
2024/5/17
Journal
Pediatrics
Pages
e2024066190
Publisher
American Academy of Pediatrics
Description
BACKGROUND AND OBJECTIVES
The messenger RNA (mRNA)-based coronavirus disease 2019 vaccines approved for use in children <5 years of age have different antigen doses and administration schedules that could affect vaccine immunogenicity and effectiveness. We sought to compare the strength and breadth of serum binding and neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by monovalent mRNA-based coronavirus disease 2019 vaccines in young children.
METHODS
We conducted a prospective cohort study of children 6 months to 4 years of age who completed primary series vaccination with monovalent mRNA-1273 or BNT162b2 vaccines. Serum was collected 1 month after primary vaccine series completion for the measurement of SARS-CoV-2-specific humoral immune responses, including antibody binding …
Scholar articles
T Dalapati, CA Williams, EE Giorgi, JH Hurst, S Herbek… - Pediatrics, 2024